In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 29, No. S4 ( 2014-12), p. 29-32
Kurzfassung:
H elicobacter pylori ( H . pylori ) infection is a strong risk factor for the development of gastric cancer. In 2013, the J apanese government approved H . pylori eradication therapy in patients with chronic gastritis as well as peptic ulcer. However, the continuing decline in eradication rates for first‐line H . pylori eradication therapies is an urgent problem. In this study, we investigated changes in the first‐line eradication rate from 2001 to 2010. Methods Eradication rates for 7‐day triple therapy [proton pump inhibitor (rabeprazole 20 mg, lansoprazole 60 mg, or omeprazole 40 mg) + amoxicillin 1500 mg + clarithromycin ( CAM ) 400 or 800 mg, daily] were collated from 14 hospitals in the T okyo metropolitan area. The urea breath test was used for the evaluation of eradication. The cut‐off value was less than 2.5%. Results The yearly eradication rates (intention to treat/per protocol) were 78.5/79.5% (2001, n = 242), 71.2%/72.9% (2002, n = 208), 67.8%/70.5% (2003, n = 183), 75.6%/84.6% (2004, n = 131), 56.4%/70.5% (2005, n = 114), 70.5%/75.8% (2006, n = 271), 67.4%/82.0% (2007, n = 135), 64.0%/76.3% (2008, n = 261), 60.5%/74.3% (2009, n = 329), and 66.5%/78.8% (2010, n = 370), respectively. Examination of eradication rates according to CAM dosage revealed an eradication rate of 65.6% (383/584) for CAM 400 mg daily, and 68.5% (1124/1642) for CAM 800 mg daily, with no significant difference seen between dosages. Conclusion In recent years, eradication rates for first‐line triple therapy have obviously decreased, but no noticeable decrease has occurred after 2001.
Materialart:
Online-Ressource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2014.29.issue-s4
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2014
ZDB Id:
2006782-3
Permalink